Approved until
08/31/2005. FDA shall incorporate the incremental burden from this
final rule into the existing inventory under 0910-0001 for drugs
and 0910-0338 for biologics upon resubmission of those packages to
OMB.
Inventory as of this Action
Requested
Previously Approved
03/31/2007
03/31/2007
31,555
0
0
1,023,310
0
0
0
0
0
The final rule sets forth requirements
for manufacturing changes requiring supplement submission and FDA
approval prior to the distribution of the product made using the
change, changes requiring supplement submission at least 30 days
prior to the distribution of the product, changes requiring
supplement submission at the time of distribution, and changes to
be described in an annual report.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.